A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

At Univera Healthcare, our team of clinical pharmacists uses evidence-based guidelines to make sure each drug on our formulary earns its place.

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly ...

McDonald’s Corp. shares slumped on Tuesday after Redburn Atlantic slapped the burger chain with its sole sell rating, saying ...

McDonald's stock was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Coming off a successful initial public offering, Omada Health President Wei-Li Shao said the company is focused on turning a ...